HempFusion Wellness Inc. (TSX:CBD.U) (“HempFusion” or the
“Company”), a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition, is pleased to
announce that it has entered into a large-scale distribution
agreement with Fullscript.com (“Fullscript”), a leading
eCommerce platform that allows health professionals to dispense
professional-grade natural health products. Fullscript is one of
the largest distributors in the category, providing nutritional
supplements to over 80,000 practitioners and over 600,000 patients
across the United States and Canada.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210121005282/en/
Total Care Daily Probiotic from Biome
Research (Photo: Business Wire)
This agreement signifies HempFusion’s strategic launch into the
doctor practitioner sales channel.
HempFusion’s seven Biome Research SKUs will be available to ship
from Fullscript distribution centers starting February 2, 2021.
“We are incredibly excited to launch doctor practitioner sales
starting with Biome Research, a specialized wholly-owned HempFusion
brand designed specifically for doctors, practitioners and their
patients,” stated Nancy Angelini, HempFusion’s Director of
Doctor/Practitioner. “An industry-leading eCommerce platform like
Fullscript, with a deep and established distribution network, is a
tremendous advantage to HempFusion. We expect this channel to drive
significant revenue growth for the Company,” continued
Angelini.
Biome Research products have been under development by the
Company for nearly 14 months. The products include scientifically
documented strains of beneficial and living probiotic bacteria that
utilize an exclusive and scientifically validated MAKTrek 3-D
Probiotic Delivery System. All formulations are based on
well-founded scientific research using validated methods to protect
and deliver live probiotics to the lower gastrointestinal tract.
The launch concludes many months of planning and preparation,
including procurement of the product ingredients, final SKU
productions and logistics.
“The launch into the doctor practitioner sales channel is
crucial. It is a major component of the Company’s broader
five-channel distribution strategy, which includes planned
expansion in Natural, eCommerce, Food & Drug Mass, and
Convenience channels,” stated Jason Mitchell, N.D, HempFusion’s
Chief Executive Officer.
Biome Research is a division of HempFusion’s wholly-owned
subsidiary, Probulin Probiotics, LLC.
ABOUT FULLSCRIPT
Fullscript is an online dispensary platform designed by Healthy
Web Inc. that allows health professionals to dispense the
industry’s largest catalogue of professional-grade natural health
products.
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition. HempFusion
distributes its family of brands, including HempFusion, Probulin
Probiotics, Biome Research, and HF Labs, to approximately 4,000
retail locations across all 50 states of the United States and
select international locations. Built on a foundation of regulatory
compliance and human safety, HempFusion’s diverse product portfolio
comprises 46 SKUs including tinctures, proprietary FDA Drug Listed
Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and
more. With a strong focus on research and development, HempFusion
has an additional 30 products under development. HempFusion is a
board member of the US Hemp Roundtable, and HempFusion’s
wholly-owned subsidiary, Probulin Probiotics, is one of the
fastest-growing probiotics companies in the United States,
according to SPINs reported data. HempFusion’s CBD products are
based on a proprietary Whole Food Hemp Complex™ and are available
in-store or by visiting HempFusion online at www.hempfusion.com or
www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and
Probulin on Twitter, Facebook and Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and
forward-looking information within the meaning of Canadian
securities legislation (collectively, “forward-looking
statements“) that relate to HempFusion’s current expectations
and views of future events. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance (often, but not always,
through the use of words or phrases such as “will likely result”,
“are expected to”, “expects”, “will continue”, “is anticipated”,
“anticipates”, “believes”, “estimated”, “intends”, “plans”,
“forecast”, “projection”, “strategy”, “objective” and “outlook”)
are not historical facts and may be forward-looking statements and
may involve estimates, assumptions and uncertainties which could
cause actual results or outcomes to differ materially from those
expressed in such forward-looking statements. No assurance can be
given that these expectations will prove to be correct and such
forward-looking statements included in this news release should not
be unduly relied upon. These statements speak only as of the date
of this news release. In particular and without limitation, this
news release contains forward-looking statements relating to the
Company’s launch into the doctor practitioner sales channel,
revenue growth, planned expansion in Natural, e-Commerce, Food Drug
Mass and Convenience sales channels and the Company’s other plans,
focus and objectives.
Forward-looking statements are based on a number of assumptions
and are subject to a number of risks and uncertainties, many of
which are beyond HempFusion’s control, which could cause actual
results and events to differ materially from those that are
disclosed in or implied by such forward-looking statements. Such
risks and uncertainties include, but are not limited to, the impact
and progression of the COVID-19 pandemic and other factors set
forth under “Forward-Looking Statements” and “Risk Factors” in the
final long form prospectus of the Company dated December 17, 2020
and available under the Company’s profile on SEDAR at
www.sedar.com. HempFusion undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law. New factors emerge from time to time, and it is not
possible for HempFusion to predict all of them or assess the impact
of each such factor or the extent to which any factor, or
combination of factors, may cause results to differ materially from
those contained in any forward-looking statement. Any
forward-looking statements contained in this news release are
expressly qualified in their entirety by this cautionary
statement.
Neither the TSX nor its Regulation Services Provider (as that
term is defined in the policies of the TSX) accepts responsibility
for the adequacy or accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210121005282/en/
Jason Mitchell, N.D. Chief Executive Officer and Director Email:
ir@hempfusion.com Phone: 416-803-5638
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Aug 2024 to Sep 2024
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Sep 2023 to Sep 2024